

Molgen

Corporate update

IMPALA the focus as funding gap remains

Molgen's Phase III pivotal trial (IMPALA) in metastatic colorectal cancer (mCRC) is now the focus for investors as both the Phase II trial (IMPULSE) in small cell lung cancer (SCLC) and Phase I trial in HIV (TEACH) are now complete. The company recently announced the results of a statistical forecast that has predicted the primary analysis of the data will most likely occur in April 2020 (95% CI: +/- five months). Cash reach has been prolonged to the end of 2018 by recent financing arrangements, and the signing of a licence and co-development agreement with Oncologie, in addition to R&D cost reductions. A new study with lefitolimod in HIV (TITAN) is expected to be initiated by Aarhus University Hospital in 2018. We value Molgen at €243m (€6.5/share).

Year end	Revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/16	0.0	(20.8)	(0.84)	0.0	N/A	N/A
12/17	0.0	(19.3)	(0.56)	0.0	N/A	N/A
12/18e	3.0	(14.6)	(0.39)	0.0	N/A	N/A
12/19e	0.0	(17.1)	(0.45)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

IMPULSE data interesting, focus now on IMPALA

Molgen has confirmed the initial top-line results for its 103-patient Phase II IMPULSE trial in SCLC. While it missed its primary end point, two predefined subgroups demonstrated improvements in overall survival hazard ratios. The company is currently assessing its future development options. Focus has now predominately switched to IMPALA, a 549-patient (enrolled), two-arm, randomised pivotal Phase III trial for the maintenance treatment of mCRC patients.

Oncologie: First licensing agreement signed

In February, Molgen signed a licence and co-development agreement with Oncologie potentially worth over €100m (€3m upfront), a €2m equity investment and low double-digit royalties. Previously, Molgen announced that it had signed deal terms with China-based iPharma; however, the deal was not completed.

Financials: Funding until year end

The initial payment of €3m from Oncologie in addition to recent financial arrangements has resulted in a cash reach to the end of 2018. Cash burn in Q118 was reduced to €4.6m (vs €6.0m), mainly as a result of reduction in R&D costs from the completion of the TEACH and IMPULSE studies. The initial payment from Oncologie helped reduce the pre-tax loss to €0.7m versus €5.1m in Q117.

Valuation: €243m (€6.5/share)

We value Molgen at €243m (€6.5/share) vs €256m (€7.43/share) previously. We have rolled forward our model, which is based on a risk-adjusted rNPV of lefitolimod across a range of indications and regions. Additionally, we have pushed back launches in both the EU and US for lefitolimod in CRC and SCLC to 2022 and 2024, respectively. We now also assume lefitolimod is out-licensed across indications in 2020 versus our previous assumption of 2018.


Pharma & biotech

29 May 2018

Price €0.87
Market cap €33m

Net cash (€m) at 31 March 2018	2.8
Shares in issue	37.7m
Free float	59%
Code	MGN
Primary exchange	Frankfurt (Prime Standard)
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	(6.5)	(60.9)	(80.3)
Rel (local)	(8.5)	(62.2)	(80.7)
52-week high/low	€4.4	€0.9	

Business description

Molgen is a German biopharmaceutical company developing novel biopharmaceuticals. Lead product lefitolimod (TLR9 agonist) is being evaluated in metastatic colorectal cancer maintenance, small cell lung cancer maintenance, HIV and a combination trial in advanced solid malignancies.

Next events

HY17 results	9 August 2018
IMPULSE full data presented at scientific conference	Autumn 2018
IMPALA primary analysis	H120

Analysts

Dr Daniel Wilkinson	+44 (0)20 3077 5734
Dr Susie Jana	+44 (0)20 3077 5700

healthcare@edisongroup.com
[Edison profile page](#)

**Molgen is a research client of
Edison Investment Research
Limited**

TLR9 in the headlines as IMPALA takes centre stage

In 2017, Mologen's exploratory Phase II SCLC IMPULSE trial and its Phase Ib/IIa HIV TEACH trial completed and investor attention is now focused on the most advanced clinical study, the Phase III IMPALA trial in mCRC. IMPALA, a Phase III trial testing lefitolimod as a maintenance treatment in 549 mCRC patients has completed enrolment (concluded in May 2017). It is a randomised, exploratory, non-blinded, two-arm study, with a primary end point of overall survival. In April, Mologen published a data-based prediction that has forecast when the primary analysis of IMPALA will occur. It has predicted that this will most likely occur in April 2020 with a 95% confidence interval of plus/minus five months. Previous forecasts had estimated initial data were to be expected in 2019. The time period was calculated based on patient data collected up to April 2018. Mologen plans to repeat this type of analysis in order to review and, if necessary, adapt its current forecast.

In April 2018, Mologen confirmed the top-line results presented in 2017 from the now-completed exploratory Phase II IMPULSE trial. Data demonstrated that it did not meet the primary end point of overall survival. However, it showed potential, non-statistically significant advantage in two pre-specified subgroups. Patients with a low number of activated B cells and patients with chronic obstructive pulmonary disease (COPD) demonstrated improvements in overall survival hazard ratios. Patients with a low number of activated B cells demonstrated a hazard ratio of 0.53 (95% confidence interval [CI]: 0.26–1.08) and patients with COPD (a common underlying disease for lung cancer) demonstrated a 0.48 hazard ratio (95% CI: 0.20–1.17). The trial was not powered for statistical significance in these subgroups. It should be kept in mind that SCLC is a difficult disease to treat and any potential benefit that could be provided is a positive. Mologen is currently assessing its options for future development.

Top-line data from TEACH, an exploratory, non-randomised Phase Ib/IIa trial testing lefitolimod in HIV-positive patients, failed the primary end point of reduction in viral reservoir in 12 patients receiving both antiretroviral therapy and lefitolimod. However, an increased duration of viral control above what is typically expected was observed in one patient out of nine after stopping ART. A new trial, designated TITAN, plans to test lefitolimod in combination with virus-neutralising antibodies and is planned to start in 2018. The trial will be run by Aarhus University Hospital in Denmark. In January 2017, Aarhus received a \$2.75m grant from Gilead to fund the trial. The antibodies have been developed by Rockefeller University in New York.

We note TLR9 therapies, of which Mologen's lead candidate lefitolimod is one, continue to gain industry-wide traction; most recently, sector-wide attention was generated by a publication in the journal [Science](#). In a preclinical study, it was demonstrated that a combination of a TLR9 agonist with an OX40 antibody cured mice of existing cancers. These and other immune combinations continue to gain traction and multiple approaches are being tested, including a [Phase I trial](#) run by MD Anderson Cancer Center, testing Mologen's lefitolimod with Yervoy (CTLA-4 inhibitor). Mologen additionally continues to progress its next-generation TLR9 agonists EnanDIM, with data most recently [presented at AACR](#).

In April, it was announced that Dr Mariola Söhnngen will be stepping down as the CEO as of 31 October. Mologen has begun the search for a successor.

Oncologie: First licensing agreement for lefitolimod

In February, Mologen signed a licence and co-development agreement with Oncologie potentially worth over €100m (€3m upfront), a €2m equity investment and double-digit royalties. Oncologie is a

Boston-headquartered, private oncology therapeutics company with operations additionally in Shanghai, China. Mologen had previously announced in 2017 that it had signed deal terms with China-based iPharma. After the end of an exclusivity period, Mologen entered discussions and negotiations with Oncologie. The contract comprises two parts.

First, a licence agreement through which Mologen grants Oncologie an exclusive licence for the development, manufacturing and commercialisation of lefitolimod in China, Hong Kong, Macao, Taiwan and Singapore. The second part is a global co-development partnership, which aims to utilise Oncologie's novel biomarkers. Both parties will share the economic returns from global joint development pursuant to both parties' contributions; however, all costs relating to development, registration, marketing and commercialisation of lefitolimod in any territory are to be covered by Oncologie.

Mologen has received an initial payment of €3m and a €2m equity investment by Oncologie is expected within 12 months of the initial payment. Additional development and commercialisation milestones are expected and total payments could be more than €100m. They are due on reaching predefined development steps as well as market approval. In addition, sales-related commercial milestones are defined. Finally, Mologen will receive low double-digit royalties on sales.

Valuation: €243m (€6.5/share)

We now value Mologen at €243m (€6.5/share) versus €256m (€7.43/share) previously. The valuation is based on a risk-adjusted, sum-of-the-parts DCF model, applying a standard 12.5% discount rate and including 31 March 2018 net cash of €2.8m. With the delay in anticipated data readout for IMPALA, we have pushed lefitolimod's forecast launch in mCRC back to 2022 from 2021 in the US and 2020 in the EU. We assume based on historic data that the creation of a regulatory package for the FDA/EMA is likely to take between eight and 12 months with the review of a regulatory submission taking 12 months. As such we assume a launch in both markets is most likely in early 2022, however variability in timings related to these aforementioned processes mean a launch as early as late 2021 could be possible.

With the uncertainties around the next stages of development for lefitolimod in SCLC, we have pushed back the launch dates to 2024 from 2022 in both the EU and the US. We no longer assume lefitolimod will be out-licensed in 2018 in the EU and the US. We now assume it will be out-licensed across indications in 2020 once IMPALA data have been published. We note that the terms of any potential future licensing deal for lefitolimod will heavily influence financing needs, while a delay or failure to achieve out-licensing could materially affect Mologen's long-term financial position.

At this time, we assume Mologen will be able to negotiate a higher royalty rate in mCRC and now assume this at 35% (versus 25% previously). We additionally assume that a partner will fund a Phase III trial for SCLC. A summary of our valuation assumptions can be seen in Exhibit 1. For a full breakdown of our valuation, please see our previously published outlook note ([Lefitolimod trial readouts hint at future potential](#)).

Exhibit 1: Valuation assumptions

Product	Status	Market launch	NPV (€m)	Peak sales (\$m)	Probability of success	Royalty estimate	rNPV (€m)	rNPV share (€)	Key assumptions
Lefitolimod CRC – US	Phase III-ready	2022	111	303	65%	30%	70.5	1.87	~135,000 CRC cases/year; 25% metastatic + 5% regional; 60% chemo response; 25% peak share; \$40,000 treatment price; 2028 patent expiry
Lefitolimod CRC – EU	Phase III	2022	207	572	65%	30%	133.1	3.53	~345,000 CRC cases/year; 25% metastatic + 5% regional; 60% chemo response; 25% peak share; \$30,000 treatment price; 2030 patent expiry
Lefitolimod SCLC – US	Phase II-ready	2024	19	118	15%	15%	2.6	0.07	~225,000 lung cancer cases/year; 15% SCLC; 75% advanced SCLC; 70% chemo response; 15% peak share; \$40,000 price; 2028 patent expiry
Lefitolimod SCLC – EU	Phase II	2024	9	124	15%	15%	0.4	0.01	~310,000 lung cancer cases/year; 15% SCLC; 75% advanced SCLC; 70% chemo response; 15% peak share; \$30,000 price; 2030 patent expiry
Lefitolimod HIV – WW	Phase I	2025	72	405	15%	15%	7.5	0.19	~36.7m cases (prevalence); 46% treated; 5% peak share; \$20,000 price; patent expiry 2036 (expected, not yet granted)
Lefitolimod & ICI – ASM (SCLC used as model) – WW	Phase I	2028	62	511	15%	15%	8.6	0.23	~1.8m lung cancer cases worldwide; 12.50% SCLC; 5% peak share; \$30,000 price; patent expiry 2036 (expected, not yet granted)
Lefitolimod mCRC – China	Phase I	2028	70	203	5%	15%	18.1	0.48	~200,000 CRC cases/yr; 25% metastatic + 5% regional; 60% chemo response; 10% will receive additional treatment; 1% peak share; €5,000; patent expiry unknown
Portfolio value			810				240.52	6.38	
Cash							2.8	0.07	Net cash 31 March 2018
Total							243	6.46	37.7m shares out

Source: Edison Investment Research

Financials

Gross cash at 31 March 2018 was €8.3m (net cash €2.8m). Our model suggests that current cash is sufficient to fund operations to end 2018; a funding gap remains in respect of the IMPALA study and combination readout. Our model includes €20m of illustrative debt in 2019 to fill this funding gap.

In Q118, Mologen reported €3m in revenue from the Oncologie deal. Cost of materials in Q118 was reduced to €1.6m (vs €3.0m in Q118), mainly as a result of reduction in R&D costs from the completion of the TEACH and IMPULSE studies. We expect the trend in reduced R&D costs to continue with forecast cost of materials for FY18 of €8.3m versus €9.7m in 2017. We forecast a net loss for FY18 of €14.6m versus €19.3m in 2017.

To continue to fund the company, Mologen has engaged in a variety of funding activities in Q118.

In February, Mologen entered into an agreement with Luxembourg-based financing provider European High Growth Opportunities Securitization Fund (EHGO). Under this agreement, Mologen can, over a two-year period, require EHGO to subscribe to convertible bonds. The bonds can be issued in amounts of €500,000 in 24 tranches for a total of €12m. Bonds must be converted 12 months after issuance and they do not accrue interest. As of Q118 results, two tranches have been exercised and both have been converted. We note existing shareholders will face some, albeit small, share dilution if future bonds are exercised. We assume a further six tranches are drawn down in 2018.

In March, Mologen announced a rights issue from authorised capital to national and international investors. 2,357,368 new shares were issued at a subscription price of €2.12. Overall, the company generated gross proceeds of around €5m. For details of all of Mologen's existing financial arrangements, including previously subscribed convertible bonds, please see our outlook note [Lefitolimod trial readouts hint at future potential](#).

Exhibit 2: Financial summary

€000s	2015	2016	2017	2018e	2019e
Year end 31 December	IFRS	IFRS	IFRS	IFRS	IFRS
PROFIT & LOSS					
Revenue	39	74	47	3,000	40
Cost of Sales	0	0	0	0	0
Gross Profit	39	74	47	3,000	40
Research and development (cost of materials)	(11,681)	(11,780)	(9,752)	(8,289)	(7,875)
Selling, general & administrative (personnel expenses)	(5,074)	(5,453)	(5,093)	(5,042)	(4,992)
Other operating income / expense	(3,702)	(3,418)	(3,860)	(3,884)	(3,845)
EBITDA	(20,418)	(20,577)	(18,658)	(14,215)	(16,671)
Operating Profit (before amort. and except.)	(20,499)	(20,813)	(18,684)	(14,218)	(16,677)
Intangible Amortisation	(40)	(172)	(23)	(9)	(5)
Exceptionals/Other	0	0	0	0	0
Operating Profit	(20,539)	(20,985)	(18,707)	(14,226)	(16,682)
Net Interest	3	(18)	(574)	(422)	(426)
Other	0	0	0	0	0
Profit Before Tax (norm)	(20,496)	(20,831)	(19,258)	(14,640)	(17,103)
Profit Before Tax (FRS 3)	(20,536)	(21,003)	(19,281)	(14,649)	(17,108)
Tax	0	0	0	0	0
Deferred tax	0	0	0	0	0
Profit After Tax (norm)	(20,496)	(20,831)	(19,258)	(14,640)	(17,103)
Profit After Tax (FRS 3)	(20,536)	(21,003)	(19,281)	(14,649)	(17,108)
Average Number of Shares Outstanding (m)	20.7	24.7	34.3	37.7	37.7
EPS - normalised (c)	(0.99)	(0.84)	(0.56)	(0.39)	(0.45)
EPS - FRS 3 (c)	(0.99)	(0.85)	(0.56)	(0.39)	(0.45)
Dividend per share (c)	0.0	0.0	0.0	0.0	0.0
BALANCE SHEET					
Fixed Assets	414	62	44	66	89
Intangible Assets	175	37	17	10	6
Tangible Assets	239	25	27	56	83
Other	0	0	0	0	0
Current Assets	25,981	21,300	8,061	2,712	6,008
Stocks	28	13	16	16	16
Debtors	0	33	13	13	13
Cash	24,592	20,520	6,523	1,175	4,470
Other	1,361	734	1,509	1,509	1,509
Current Liabilities	(6,886)	(7,404)	(7,502)	(7,502)	(7,502)
Creditors	(6,390)	(6,530)	(4,400)	(4,400)	(4,400)
Short term borrowings	0	0	0	0	0
Other	(496)	(874)	(3,102)	(3,102)	(3,102)
Long Term Liabilities	(6)	(2,121)	(5,474)	(9,470)	(29,897)
Long term borrowings	0	(2,119)	(5,419)	(9,415)	(29,842)
Other long term liabilities	(6)	(2)	(55)	(55)	(55)
Net Assets	19,503	11,837	(4,871)	(14,194)	(31,302)
CASH FLOW					
Operating Cash Flow	(15,095)	(19,270)	(19,696)	(15,061)	(17,097)
Net Interest	0	18	574	424	427
Tax	12	0	0	0	0
Capex	(95)	(57)	(33)	(33)	(34)
Acquisitions/disposals	0	13	35	0	0
Financing	26,207	12,706	477	5,326	0
Dividends	0	0	0	0	0
Other	0	0	0	0	0
Net Cash Flow	11,029	(6,590)	(18,643)	(9,344)	(16,705)
Opening net debt/(cash)	(13,563)	(24,592)	(18,401)	(1,104)	8,240
HP finance leases initiated	0	0	0	0	0
Exchange rate movements	0	1	(8)	0	0
Other	0	398	1,354	0	(427)
Closing net debt/(cash)	(24,592)	(18,401)	(1,104)	8,240	25,372

Source: Mologen, Edison Investment Research.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Mologen and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.